Want to see GB:RENX full AI Analyst Report?

Renalytix (RENX) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of Renalytix stock?

The P/E ratio of {name} is N/A.

21 Followers

Earnings Data

Report Date

Nov 03, 2026

TBA (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

―

Last Year’s EPS

―

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2024

Earnings Call Date:May 15, 2024|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.

Company Guidance

During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.

Positive Medicare Coverage Developments

Medicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.

Inclusion in International Clinical Guidelines

KidneyIntelX was included in the KDIGO international clinical guidelines for chronic kidney disease, marking a significant milestone for broader adoption.

Successful Fundraising

Completed common stock equity financing rounds in March and April, raising net proceeds of approximately $13.5 million, extending the financial runway.

FDA-Authorized Product Launch

Launched the FDA-authorized KidneyIntelX.dkd product version, with commercial test orders now being received.

Cost Reduction Achievements

Year-over-year headcount reduction of 50% and overall operating expenses reduced by approximately 40%, aiming for further expense reductions.

Direct-to-Physician Sales Growth

Achieved a 33% increase in direct-to-primary-care test order rates quarter-over-quarter, indicating early growth trends.

Strategic Acquisition Interest

Received interest from multiple potential acquirers, with a competitive sale process anticipated.

Renalytix (GB:RENX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:RENX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 03, 2026	2026 (Q4)	- / -	―	―	―	―
Mar 26, 2026	2026 (Q2)	- / -0.02	-0.05	68.00% (+0.03)	―	―
Nov 26, 2025	2026 (Q1)	- / -	-0.03	―	―	―
Nov 03, 2025	2025 (Q4)	- / -	-0.03	―	―	―
Jun 17, 2025	2025 (Q3)	- / -	-0.08	―	―	―
Mar 18, 2025	2025 (Q2)	- / -0.04	-0.034	-11.11% (>-0.01)	―
Nov 20, 2024	2025 (Q1)	- / -	-0.041	―	―	―
Oct 01, 2024	2024 (Q4)	-0.01 / -0.03	-0.041	27.27% (+0.01)	―	―
May 15, 2024	2024 (Q3)	-0.03 / -0.03	-0.052	42.86% (+0.02)	―
Feb 15, 2024	2024 (Q2)	-0.03 / -0.03	-0.052	35.71% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:RENX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 26, 2026	2.20 p	2.35 p	+6.82%
Nov 26, 2025	6.75 p	6.75 p	0.00%
Nov 03, 2025	8.25 p	7.38 p	-10.55%
Jun 17, 2025	7.25 p	7.25 p	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Renalytix (GB:RENX) report earnings?

Renalytix (GB:RENX) is schdueled to report earning on Nov 03, 2026, TBA (Confirmed).

What is Renalytix (GB:RENX) earnings time?

Renalytix (GB:RENX) earnings time is at Nov 03, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Renalytix stock?

The P/E ratio of Renalytix is N/A.

What is GB:RENX EPS forecast?

Currently, no data Available